Certolizumab Subcutaneous and Talimogene laherparepvec Injection
Determining the interaction of Certolizumab Subcutaneous and Talimogene laherparepvec Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:If you are currently being treated or have recently been treated with certolizumab, you should let your doctor know before receiving talimogene laherparepvec. Depending on the dose and length of time you have been on certolizumab, you may be at risk for developing a potentially life-threatening herpes infection from exposure to talimogene laherparepvec. In some situations, your doctor may want to delay treatment with talimogene laherparepvec to give your body time to recover from the effects of certolizumab therapy. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.
MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.
- "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.
Generic Name: certolizumab
Brand name: Cimzia, Cimzia Starter
Synonyms: Certolizumab, Certolizumab Pegol
Generic Name: talimogene laherparepvec
Brand name: Imlygic
Synonyms: Talimogene laherparepvec, Talimogene Laherparepvec
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Certolizumab Subcutaneous-Taliva
- Certolizumab Subcutaneous-Taltz
- Certolizumab Subcutaneous-Taltz (Ixekizumab Auto-Injectors)
- Certolizumab Subcutaneous-Taltz (Ixekizumab Prefilled Syringes)
- Certolizumab Subcutaneous-Talwin
- Certolizumab Subcutaneous-Talwin Injection
- Talimogene laherparepvec Injection-Certolizumab Vials
- Talimogene laherparepvec Injection-Cerubidine
- Talimogene laherparepvec Injection-Cervarix
- Talimogene laherparepvec Injection-Cervarix Intramuscular
- Talimogene laherparepvec Injection-Cervidil
- Talimogene laherparepvec Injection-Cesamet